Core Viewpoint - The announcement from the company reflects a strong commitment to its long-term value and future prospects, as demonstrated by the voluntary shareholding commitment from key executives [1] Group 1: Shareholder Commitment - Dr. Wu Jinzi and He Jingdao have voluntarily committed not to sell or pledge any shares they control until the release of three key clinical trial data points [1] - The three clinical data readouts include: (i) top-line data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025; (ii) top-line data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025; and (iii) top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected by December 2025 [1] - As of the announcement date, the total number of voluntarily locked-up shares held by Dr. Wu and his wife amounts to 576 million shares, representing approximately 58.03% of the company's existing issued share capital (excluding treasury shares) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出。 本公司董事（「董事」）會（「董事會」）謹此宣布，其獲告知，為表達對本公司長遠 價值及未來前景的堅定信心，吳勁梓博士（歌禮創始人、董事會主席兼首席執行 官、及本公司控股股東，「吳博士」），與何淨島（本公司執行董事及控股股東、吳 博士之配偶，「吳夫人」）一起，已自願承諾在如下3個臨床數據讀出前，不會出 售（包括但不限於出售或質押）任何由彼等或彼等各自控制的實體直接或間接實益 擁有的本公司股份（「股份」）：(i) ASC47聯合司美格魯肽在肥胖受試者中進行的 美國I期臨床研究頂線數據，預計於2025年9月底獲得；(ii) ASC30口服片在肥胖 或超重受試者中進行的美國13周IIa期臨床研究頂線數據，預計於2025年12月獲 得；及(iii) ASC50在健康受試者中進行的美國I期單劑量遞增研究頂線數據，預 計於202 ...